Get started
Author

А. Yu. Goryainova

Observed names: A. Y. Goryainova, A. Yu. Goryainova, AYu Goryainova, Alla Goryainova, Alla Yu. Goryainova, А Ю Горяйнова, А. Y. Goryainova, А. Ю. Горяинова, А.Ю. Горяинова, Алла Горяинова, Горяинова А.Ю., Горяинова Алла Юрьевна
ORCID: 0000-0001-7127-7945
Observed ORCID: 0000-0001-7127-7945
OpenAlex ID: A5082375361
Toxicity and efficacy of gemcitabine plus nab-paclitaxel (paclitaxel + albumin) in a Russian patient population: results of a multicenter retrospective study
2019 · I. A. Pokataev, M. A. Lyadova, et al. · Malignant tumours · 4
PDF
Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender
2022 · A. I. Stukan, R.  A. Murashko, et al. · Head and neck tumors (HNT) · 3
PDF
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
2022 · Tatyana N. Sokolova, Tatyana I. Solov'eva, et al. · Journal of Modern Oncology · 3
PDF
Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
2025 · Tatyana N. Sokolova, Grigory A. Yanus, et al. · Cancers · 2
PDF
Quantitative single-photon emission computed tomography/computed tomography in assessing the effectiveness of radium-223 dichloride therapy
2024 · E. A. Nikolaeva, A. S. Krylov, et al. · Cancer Urology · 2
PDF
Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
2023 · A. A. Rumyantsev, A. E. Protasova, et al. · Tumors of female reproductive system · 2
PDF
Dynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy
2022 · A. I. Stukan, A. Yu. Goryainova, et al. · Bulletin of Siberian Medicine · 2
Germinal BRCA-mutation significance in the tumor microenvironment formation Efficacy of PARP inhibition in late-line therapy of metastatic castration-resistant prostate cancer
2021 · A. I. Stukan, A. Yu. Goryainova, et al. · Cancer Urology · 2
PDF
Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
2024 · A. A. Rumyantsev, A. E. Protasova, et al. · Tumors of female reproductive system · 1
PDF
Effect of Differences in the Expression Levels Steroid Hormone Receptors and HER2 in the Primary Tumor and Metastatic Focus on the Efficacy of Eribulin Monotherapy in Metastatic Breast Cancer
2023 · Анастасия Стукань, Роман Мурашко, et al. · Voprosy Onkologii · 1
PDF
Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision
2023 · A. Yu. Goryainova, R. A. Murashko, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
Androgen receptor signaling mechanism in prostate cancer: resistance to antiandrogen therapy and association with DNA repair genes
2023 · A. I. Stukan, A. Yu. Goryainova, et al. · Cancer Urology · 1
Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
2022 · A. S. Tyulyandina, E. A. Ulrikh, et al. · Tumors of female reproductive system · 1
PDF
Hepatocellular cancer of non-viral etiology: more questions than answers?
2022 · V. V. Breder, I. A. Pokataev, et al. · Medical alphabet · 1
PDF
Tumor immune microenvironment and apoptotic markers in breast cancer patients carrying BRCA1 gene mutations
2022 · A. I. Stukan, A. Yu. Goryainova, et al. · Tumors of female reproductive system · 1
PDF
Clinical and prognostic characteristics of BRCA1/2-associated breast cancer depending on the type of mutation: estrogen signaling pathway and secondary tumors
2022 · A. I. Stukan, A. Yu. Goryainova, et al. · Tumors of female reproductive system · 1
PDF
Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer
2022 · A. Yu. Goryainova, A. I. Stukan, et al. · Meditsinskiy sovet = Medical Council · 1
Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive BRCA-related breast cancer
2022 · A. I. Stukan, A. Yu. Goryainova, et al. · Tumors of female reproductive system · 1
PDF
Efficacy of pembrolizumab plus lenvatinib versus alternative drug regimens in patients with recurrent endometrial cancer after platinum based chemotherapy: a retrospective cohort study
2026 · Angelina N. Letuchikh, A. А. Rumyantsev, et al. · Surgery and Oncology
Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality
2025 · N. A. Avxentyev, E. V. Bilan, et al. · Tumors of female reproductive system
PDF
Efficacy of alpelisib with rational use of metformin in HR+/HER2- advanced breast cancer patients with PIK3CA mutations (m): retrospective analysis in routine practice of several Russian centers
2025 · D. A. Filonenko, R. V. Orlova, et al. · Siberian Journal of Oncology
PDF
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
2024 · A. E. Protasova, A. A. Rumyantsev, et al. · Tumors of female reproductive system
PDF
New treatment options for HER2-positive metastatic breast cancer with leptomeningeal metastases
2024 · A. Yu. Goryainova, S. V. Sharov, et al. · Meditsinskiy sovet = Medical Council
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice at several Russian centers.
2024 · Lyudmila Zhukova, Daria Filonenko, et al. · Journal of Clinical Oncology
PDF
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).
2024 · Daria Filonenko, Rashida Orlova, et al. · Journal of Clinical Oncology
PDF
Works count: 48
Citation count: 30
H-index: 3
I10-index:
Year
Topic
Type